{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.0","upperLimit":"99.7","value":"55.6"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"100.0","value":"77.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.","id":"OG000","title":"Cytarabine+Daunorubicin+Etoposide"},{"description":"Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.","id":"OG001","title":"Clofarabine+Cytarabine"}],"paramType":"NUMBER","populationDescription":"Randomized patients who received NK cell therapy after chemotherapy","reportingStatus":"POSTED","timeFrame":"3 years after completion of therapy","title":"Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}